시장보고서
상품코드
1429678

세계의 혈관내피성장인자(VEGF) 억제제 시장 보고서(2024년)

Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

혈관내피성장인자(VEGF) 억제제 시장 규모는 향후 몇 년 동안 크게 성장할 것으로 예상됩니다. 2028년까지 연평균 7.5%의 복합 성장률(CAGR)로 139억 8,000만 달러 규모로 성장할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 암 유병률 증가, 연령 관련 황반변성(AMD) 발생 증가, 의료비 증가, 신흥국의 큰 잠재력, 바이오시밀러 의약품의 보급, 노인 인구 증가 등 여러 요인으로 인해 발생할 것으로 예상됩니다. 이 기간 동안 예상되는 주요 동향으로는 환자 예후를 개선하기 위한 진행성 암에 대한 병용요법 제공, 혁신을 촉진하고 카테고리 리더십을 확립하기 위한 전략적 제휴, 효과적이고 혁신적인 의약품을 만들기 위한 R&D 활동에 대한 대규모 투자, 바이오시밀러 생산에 대한 집중 등이 있습니다. 바이오시밀러 생산에 집중하고 있습니다. 시장 범위를 확장하고, 치료의 경제성을 높이고, 삼출성 연령 관련 황반변성(AMD)의 복용량을 줄여 환자들의 복지를 향상시키는 데 집중할 것입니다.

VEGF 억제제 시장은 암과 황반변성 유병률 증가로 인해 성장할 것으로 예상됩니다. 예를 들어, 2022년 8월 국립의학도서관이 발표한 체계적 문헌인사이트 및 메타분석에 따르면, 연령 관련 황반변성이 전 세계 인구의 8.7%에 영향을 미칠 것으로 예상됩니다. 2020년에는 이 질환을 앓고 있는 인구가 1억 9,600만 명에 달하며, 2040년에는 2억 8,800만 명으로 증가할 것으로 예측됩니다. 질병의 진행을 억제하고 시력을 개선하는 항혈관내피성장인자(항VEGF) 약물은 이 질환의 진행을 억제하는 데 중요한 역할을 합니다. 이러한 상태를 관리하는 것입니다. 혈관내피성장인자(VEGF) 억제제는 암 발생 시 종양 성장을 제한하는 데에도 중요한 역할을 합니다. 따라서 암 및 황반변성의 유병률 증가는 예측 기간 동안 VEGF 억제제 시장의 확대에 기여할 것입니다.

당뇨망막병증 유병률 증가는 혈관내피성장인자(VEGF) 억제제 시장 성장의 원동력이 될 것으로 예상됩니다. 망막에 영향을 미치는 당뇨병과 관련된 안질환인 당뇨망막병증은 심각한 문제입니다. 항 VEGF 약물로도 알려진 VEGF 억제제는 안구 혈관의 비정상적인 증식과 관련된 단백질인 VEGF를 억제함으로써 당뇨망막병증 치료에 중요한 역할을 합니다. 2021년 미국 실명예방협회(Prevent Blindness)는 미국에서 약 960만 명이 당뇨망막병증을 앓고 있으며, 시력을 위협하는 당뇨망막병증은 184만 명에게 영향을 미치고 있다고 보고했습니다. 따라서 당뇨망막병증 유병률의 증가는 혈관내피성장인자(VEGF) 억제제 시장의 성장을 촉진하는 중요한 요인이 될 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나·러시아 전쟁이 시장에 미치는 영향
  • COVID-19에 의한 시장에 대한 영향

제5장 세계 시장 규모와 성장

  • 세계의 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계의 시장 규모 실적과 성장, 2018-2023년
  • 세계의 시장 규모 예측과 성장, 2023-2028년, 2033년

제6장 시장 세분화

  • 세계의 혈관내피성장인자(VEGF) 억제제 시장, 약제 유형별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • Avastin
  • Tecentriq
  • Cometriq
  • Eylea
  • 기타 약제 유형
  • 세계의 혈관내피성장인자(VEGF) 억제제 시장, 투여 경로별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 경구
  • 정맥내
  • 세계의 혈관내피성장인자(VEGF) 억제제 시장, 용도별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 종양학
  • 안과
  • 기타 용도

제7장 지역 및 국가 분석

  • 세계의 혈관내피성장인자(VEGF) 억제제 시장, 지역별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 세계의 혈관내피성장인자(VEGF) 억제제 시장, 국가별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 상황과 기업 개요

  • 혈관내피성장인자(VEGF) 억제제 시장 경쟁 상황
  • 혈관내피성장인자(VEGF) 억제제 시장 기업 개요
    • F. Hoffmann-La Roche AG
    • Bayer AG
    • Regeneron Pharmaceuticals Inc.
    • AstraZeneca Plc.
    • Novartis AG

제31장 기타 주요 및 혁신적인 기업

  • Pfizer Inc.
  • Eli Lilly and Company
  • Exelixis Inc.
  • Amgen Inc.
  • Sanofi SA
  • Cipla Limited
  • Biocon
  • Dr. Reddy's Laboratories
  • Chi-Med
  • Innovent Biologics
  • Daiichi Sankyo
  • Chugai Pharmaceutical Co. Ltd
  • AstraZeneca plc
  • Allergan plc.
  • Boehringer Ingelheim International GmbH

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병

제35장 향후 전망과 가능성 분석

제36장 부록

ksm 24.03.21

A Vascular Endothelial Growth Factor (VEGF) inhibitor is a substance that hinders programmed cell death by acting as an anti-apoptotic factor for hematopoietic cells. VEGF, a growth factor, promotes vascular permeability, potentially facilitating the spread of tumors through the bloodstream and enhancing their access to oxygen and nutrients.

The primary categories of VEGF inhibitors include Avastin, Tecentriq, Cometriq, Eylea, and others. Avastin is a medication designed to assist individuals with wet age-related macular degeneration (AMD). Additionally, it is utilized to treat diabetic eye issues and other retinal conditions. Administered into the eye, Avastin helps delay the loss of eyesight associated with certain disorders. Various routes of administration, including oral and intravenous, are employed in the fields of oncology, ophthalmology, and other medical domains.

The vascular endothelial growth factor (VEGF) inhibitor market research report is one of a series of new reports from The Business Research Company that provides vascular endothelial growth factor (VEGF) inhibitor market statistics, including vascular endothelial growth factor (VEGF) inhibitor industry global market size, regional shares, competitors with a vascular endothelial growth factor (VEGF) inhibitor market share, detailed vascular endothelial growth factor (VEGF) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the vascular endothelial growth factor (VEGF) inhibitor industry. This vascular endothelial growth factor (VEGF) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The vascular endothelial growth factor (vegf) inhibitor market size has grown strongly in recent years. It will grow from $9.68 billion in 2023 to $10.46 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The historical period's growth can be ascribed to the rise in cancer prevalence, robust economic expansion in emerging markets, heightened pharmaceutical research and development (R&D) expenditures, increased healthcare spending, government initiatives, and the rapid growth of the elderly population.

The vascular endothelial growth factor (vegf) inhibitor market size is expected to see strong growth in the next few years. It will grow to $13.98 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The anticipated growth in the forecast period can be attributed to the increasing prevalence of cancer, a rise in the occurrence of age-related macular degeneration (AMD), elevated healthcare expenditures, the substantial potential of emerging economies, widespread adoption of biosimilar drugs, and the growing geriatric population. Key trends expected in this period involve providing combination therapies for advanced cancers to enhance patient outcomes, strategic collaborations to drive innovations and establish category leadership, extensive investments in research and development activities for the creation of effective and innovative drugs, a focus on biosimilar production to broaden market reach and make treatments more affordable, and a concentration on reducing dosages for wet age-related macular degeneration (AMD) to enhance patient well-being.

The VEGF inhibitor market is anticipated to experience growth, propelled by the increasing prevalence of cancer and macular degeneration diseases. For instance, a systematic review and meta-analysis published by the National Library of Medicine in August 2022 highlighted that age-related macular degeneration is expected to affect 8.7% of the global population. In 2020, the condition affected 196 million individuals, and this number is projected to rise to 288 million by 2040. Anti-vascular endothelial growth factor (anti-VEGF) agents, which inhibit the progression of the disease and improve vision, are crucial in managing these conditions. Vascular endothelial growth factor (VEGF) inhibitors also play a vital role in restricting tumor growth during cancers. Therefore, the growing prevalence of cancer and macular degeneration diseases contributes to the expansion of the VEGF inhibitor market during the forecast period.

The increasing prevalence of diabetic retinopathy is expected to be a driving force behind the growth of the vascular endothelial growth factor (VEGF) inhibitor market. Diabetic retinopathy, a diabetes-related eye condition affecting the retina, is a significant concern. VEGF inhibitors, also known as anti-VEGF medications, play a crucial role in treating diabetic retinopathy by inhibiting VEGF, a protein associated with the abnormal growth of blood vessels in the eye. In 2021, Prevent Blindness reported that diabetic retinopathy affected an estimated 9.6 million people in the United States, with vision-threatening diabetic retinopathy impacting 1.84 million individuals. Consequently, the increasing prevalence of diabetic retinopathy is a key factor propelling the growth of the vascular endothelial growth factor (VEGF) inhibitor market.

Key players in the VEGF inhibitor industry are engaging in various collaborations and partnerships to broaden their product portfolios through the development of new products. Expanding the product portfolio is a strategic approach employed by companies to enhance business growth and increase market share by meeting consumer demand. The product development process involves the conceptualization, design, development, and marketing of newly created or rebranded goods or services. For instance, in September 2021, AbbVie, a US-based pharmaceutical company, entered into a partnership with REGENXBIO Inc., a US-based biotechnology company, to collaborate on the development and commercialization of RGX-314, an experimental gene therapy targeting chronic retinal diseases such as diabetic retinopathy and wet age-related macular degeneration. RGX-314 utilizes the NAV AAV8 vector to encode an antibody fragment that inhibits vascular endothelial growth factor (VEGF). The therapy is designed to block the VEGF pathway responsible for the development of new, leaky blood vessels and fluid buildup in the retina. As part of the agreement, AbbVie made an upfront payment of $370 million to REGENXBIO, with potential additional payments of up to $1.38 billion upon achieving further development, regulatory, and commercial milestones.

Major companies in the VEGF inhibitors market are dedicated to introducing innovative products through collaborations to maximize their revenues. Collaborative innovation involves developing new ideas, products, or services through partnerships with external entities such as customers, suppliers, and other stakeholders. For instance, in June 2022, Biogen Inc., a US-based biotechnology company, and Samsung Bioepis Co. Ltd., a South Korea-based biopharmaceutical company, jointly launched BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS (ranibizumab). BYOOVIZ, the first ophthalmology biosimilar in the United States, offers expanded alternatives and cost reduction for existing anti-VEGF treatments. It can be used to treat conditions such as Myopic Choroidal Neovascularization (mCNV), Macular Edema Following Retinal Vein Occlusion (RVO), and Neovascular (Wet) Age-Related Macular Degeneration (AMD), as it is a vascular endothelial growth factor (VEGF) inhibitor.

In January 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, acquired the worldwide license for Fruquintinib, a highly selective oral VEGFR1/2/3 tyrosine kinase inhibitor, from HUTCHMED Limited for an undisclosed amount. Under the agreement, Takeda gains exclusive global rights to develop and market fruquintinib for all indications and regions outside mainland China, Hong Kong, and Macau. HUTCHMED Limited, a China-based pharmaceutical company, specializes in the development of vascular endothelial growth factor receptor (VEGFR) 1/2/3.

Major companies operating in the vascular endothelial growth factor (vegf) inhibitor market report are F. Hoffmann-La Roche AG, Bayer AG, Regeneron Pharmaceuticals Inc., Astrazeneca Plc., Novartis AG, Pfizer Inc., Eli Lilly and Company, Exelixis Inc., Amgen Inc., Sanofi S.A., Cipla Limited, Biocon, Dr. Reddy's Laboratories, Chi-Med, Innovent Biologics, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd, AstraZeneca plc, Allergan plc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Ipsen, Oxurion, AVEO Oncology, Pharmstandard Group, Zentiva, Coherus BioSciences Inc., Celgene, Exelixis Inc., Regeneron Pharmaceuticals Inc., AVEO pharmaceuticals, Eisai Co. Ltd.

North America was the largest region in the vascular endothelial growth factor (VEGF) inhibitor market in 2023. Middle East is expected to be the fastest-growing region in the vascular endothelial growth factor (VEGF) inhibitor market share during the forecast period. The regions covered in the vascular endothelial growth factor (vegf) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the vascular endothelial growth factor (vegf) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The vascular endothelial growth factor (VEGF) inhibitor market consists of sales of nexavar, sunitinib, nilotinib, pazopanib, and dasatinib. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vascular endothelial growth factor (vegf) inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vascular endothelial growth factor (vegf) inhibitor? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vascular endothelial growth factor (vegf) inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drugs Type: Avastin; Tecentriq; Lucentis; Tagrisso; Cometriq; Eylea; Other Drug Types
  • 2) By Route Of Administration: Oral; Intravenous, Intravitreal
  • 3) By Application: Oncology; Ophthalmology; Other Applications
  • Companies Mentioned: F. Hoffmann-La Roche AG; Bayer AG; Regeneron Pharmaceuticals Inc.; Astrazeneca Plc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Characteristics

3. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Trends And Strategies

4. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Size and Growth

  • 5.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Segmentation

  • 6.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Avastin
  • Tecentriq
  • Cometriq
  • Eylea
  • Other Drug Types
  • 6.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Intravenous
  • 6.3. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oncology
  • Ophthalmology
  • Other Applications

7. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Regional And Country Analysis

  • 7.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 8.1. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 9.1. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
  • 9.2. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 10.1. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 11.1. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
  • 11.2. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 12.1. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 13.1. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 14.1. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
  • 14.2. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 15.1. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
  • 15.2. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 16.1. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 17.1. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 18.1. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 19.1. Italy Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 20.1. Spain Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 21.1. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
  • 21.2. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 22.1. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 23.1. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
  • 23.2. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 24.1. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
  • 24.2. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 25.1. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
  • 25.2. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 26.1. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
  • 26.2. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 27.1. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 28.1. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
  • 28.2. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

  • 29.1. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
  • 29.2. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive Landscape And Company Profiles

  • 30.1. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive Landscape
  • 30.2. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Bayer AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Regeneron Pharmaceuticals Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AstraZeneca Plc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Other Major And Innovative Companies

  • 31.1. Pfizer Inc.
  • 31.2. Eli Lilly and Company
  • 31.3. Exelixis Inc.
  • 31.4. Amgen Inc.
  • 31.5. Sanofi S.A.
  • 31.6. Cipla Limited
  • 31.7. Biocon
  • 31.8. Dr. Reddy's Laboratories
  • 31.9. Chi-Med
  • 31.10. Innovent Biologics
  • 31.11. Daiichi Sankyo
  • 31.12. Chugai Pharmaceutical Co. Ltd
  • 31.13. AstraZeneca plc
  • 31.14. Allergan plc.
  • 31.15. Boehringer Ingelheim International GmbH

32. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive Benchmarking

33. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

35. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Future Outlook and Potential Analysis

  • 35.1 Vascular Endothelial Growth Factor (VEGF) Inhibitor Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Vascular Endothelial Growth Factor (VEGF) Inhibitor Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Vascular Endothelial Growth Factor (VEGF) Inhibitor Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제